Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M401891200 on April 20, 2004

J. Biol. Chem., Vol. 279, Issue 29, 30259-30264, July 16, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/29/30259    most recent
M401891200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hama, E.
Right arrow Articles by Saido, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hama, E.
Right arrow Articles by Saido, T. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Effects of Neprilysin Chimeric Proteins Targeted to Subcellular Compartments on Amyloid {beta} Peptide Clearance in Primary Neurons*

Emi Hama, Keiro Shirotani, Nobuhisa Iwata, and Takaomi C. Saido{ddagger}

From the Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan

Received for publication, February 20, 2004 , and in revised form, March 26, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Neprilysin (NEP) is a rate-limiting amyloid {beta} peptide (A{beta})-degrading enzyme in the brain. We demonstrated previously that overexpression of neprilysin in primary cortical neurons remarkably decreased not only extracellular but also intracellular A{beta} levels. To investigate the subcellular compartments where neprilysin degrades A{beta} most efficiently, we expressed neprilysin chimeric proteins containing various subcellular compartment-targeting domains in neurons. Sec12-NEP, {beta}-galactoside {alpha}2,6-sialyltransferase-NEP, transferrin receptor-NEP, and growth-associated protein 43-NEP were successfully sorted to the endoplasmic reticulum, trans-Golgi network, early/recycling endosomes, and lipid rafts, respectively. We found that intracellularly, wild-type neprilysin and all the chimeras showed equivalent A{beta}40-degrading activities. A{beta}40 was more effectively cleared than A{beta}42, and this tendency was greater for intracellular A{beta} than for extracellular A{beta}. Wild-type and trans-Golgi network-targeted ST-NEP cleared more intracellular A{beta}42 than the other chimeras. Wild-type neprilysin cleared extracellular A{beta} more effectively than any of the chimeras, among which endoplasmic reticulum-targeted Sec12-NEP was the least effective. These observations indicate that different intracellular compartments may be involved in the metabolism of distinct pools of A{beta} (A{beta}40 and A{beta}42) to be retained or recycled intracellularly and to be secreted extracellularly, and that the endogenous targeting signal in wild-type neprilysin is well optimized for the overall neuronal clearance of A{beta}.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Accumulation of amyloid {beta} peptide (A{beta})1 in the brain is a triggering event leading to the pathological cascade of Alzheimer's disease (AD) (1). A{beta} is a physiological peptide, the steady-state level of which is strictly determined through a balance between the anabolic and catabolic activities. Changes in the metabolic balance are closely associated with A{beta} accumulation, because an increase in A{beta} anabolic activity causes A{beta} deposition in almost all cases of familial AD (2, 3). In sporadic AD brains, where elevation of anabolism seems to be rare, a reduction in catabolic activity involving A{beta}-degrading enzyme(s) has been a candidate cause that may account for A{beta} accumulation. Recently, several proteases, such as neprilysin (4), insulin-degrading enzyme (5, 6), and endothelin-converting enzymes 1 and 2 (7), have been identified as A{beta}-degrading enzymes in the brain by reverse genetic studies. Deficiencies of these proteases were associated with an elevation of brain A{beta} levels in each case, demonstrating that a reduction in the catabolic activity will also contribute to AD development by promoting A{beta} accumulation. Although these peptidases are likely to contribute to overall A{beta} clearance in the brain by complementing each other in a subcellular, cell type- and/or brain region-specific manner, neprilysin seems to play the primary role among all the A{beta}-degrading enzymes thus far examined (8, 9). It is also important that the in vivo action of neprilysin in the brain is quite selective for A{beta}; neprilysin deficiency does not elevate the levels of such "neprilysin substrate" neuropeptides as enkephalin (10), cholecystokinin, neuropeptide Y, and substance P,2 indicating the presence of redundant buffering mechanisms to metabolize these peptides. Moreover, brain neprilysin expression was selectively reduced not only in aged rodents (11) but also in the early stages of sporadic AD cases (12, 13), suggesting that up-regulation of neprilysin in the brain may prevent AD development by increasing A{beta} clearance.

Neprilysin is a type II membrane protein with a catalytic site on the extracytoplasmic side and emerges on the cell surface through the secretory pathway. A{beta} is generated in several organelles, including endoplasmic reticulum (ER), trans-Golgi network (TGN), and endosome (14, 15). Recent evidence indicates that lipid rafts, in which neprilysin is detectable (16, 17), could be involved in A{beta} generation (18, 19). We showed that not only extracellular but also cell-associated A{beta} levels were reduced by overexpression of neprilysin in primary cortical neurons using Sindbis viral vector (20), suggesting that neprilysin may degrade A{beta} through a secretory pathway and possibly on the cell surface.

In this study, we constructed several neprilysin chimeric proteins for targeting to particular organelles, such as ER, TGN, and early/recycling endosomes, and lipid raft fractions, and we investigated the sites of neuronal subcellular compartments that might be closely associated with A{beta} metabolism. For this purpose, we used well characterized organelle-targeting domains derived from type II transmembrane proteins or a transmembrane-associated protein, which show the same orientation of peptide sequence on the membrane as neprilysin. We replaced the transmembrane domain of neprilysin with that of Sec12p, which is essential for retention in ER (21). For TGN and endosome targeting, we fused the extracellular domain of neprilysin to the intracellular and transmembrane regions derived from {beta}-galactoside {alpha}2,6-sialyltransferase (ST) or transferrin receptor (TfR), which contains the TGN (22) or early/recycling endosomes (23) retention motif, respectively. Finally, the N-terminal domain of growth-associated protein 43 (GAP43) (24) was fused to the N terminus of neprilysin for delivery to the lipid raft fraction. In addition to these neprilysin chimeric proteins, we expressed wild-type and inactive mutant neprilysin as positive and negative controls, respectively, in primary cortical neurons by use of the Semliki Forest virus (SFV) gene expression system, and we examined their effects on A{beta} clearance.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Antibodies—Mouse monoclonal (56C6) and rabbit polyclonal (H-321) antibodies to the extracellular domain of human neprilysin were purchased from Novocastra Laboratories (Newcastle, UK) and Santa Cruz Biotechnology Inc. (Santa Cruz, CA), respectively. Anti-immunoglobulin heavy chain-binding protein (BiP) and anti-adaptin {gamma} mouse monoclonal antibodies were from BD Transduction Laboratories (Lexington, KY); anti-syntaxin 13 mouse monoclonal antibody was from StressGen Biotechnologies Corp. (British Columbia, Canada), and fluorochrome-conjugated secondary antibodies were from Molecular Probes (Eugene, OR). Rabbit anti-rat microtubule-associated protein-2 (MAP-2) antiserum was described previously (25).

Construction of Recombinant SFV Vectors and Infection—Human wild-type and inactive mutant neprilysin cDNAs in pBluescript II KS (+) were prepared as described previously (20, 26, 27). The cDNAs encoding neprilysin chimeric proteins for targeting of neprilysin enzyme activity to a particular organelle or lipid raft fraction, Sec12-neprilysin (NEP) to ER, ST-NEP to TGN, TfR-NEP to early/recycling endosomes, and GAP43-NEP to lipid raft fraction were constructed as follows. Neprilysin cytoplasmic domain fragment encoding amino acid residues 1–27 (NEP/CD1–27) was amplified by PCR using two oligonucleotide primers (5'-GGAAGCTTTAGGTGATGGGCAAGTCAGAAAGT-3' and 5'-GGGGCGCCCAGTGGAGTCCATCGCTGTTTCTT-3'), and then digested with HindIII and NarI. Yeast Sec12p transmembrane domain fragment (Sec12/TMD) encoding amino acid residues 355–373 was made by annealing synthetic oligonucleotides (5'-CGCCTTTTTCACCAACTTCATCCTTATTGTGCTGCTTTCTTACATTTTACAGTTCTCCTAT-3' and 5'-ATAGGAGAACTGTAAAATGTAAGAAAGCAGCACAATAAGGATGAAGTTGGTGAAAAAGG-3'). Neprilysin extracellular domain encoding amino acid residues 55–750 (NEP/ECD55–750) was constructed by ligation of a PCR product using two oligonucleotide primers (5'-GGCCCGGGATTTGCAAGTCATCAGACTGC-3' and 5'-TCCAGTGCATTCATAGTAATCTCT-3') and an XbaI-digested fragment of neprilysin cDNA in pBluescript II, and then digested with HindIII and SmaI. Finally, three DNA fragments, NEP/CD1–27, Sec12/TMD, and NEP/ECD55–750, were ligated, resulting in Sec12-NEP. For ST-NEP construction, rat ST cytoplasmic domain encoding residues 1–38 (ST/CD1–38) was amplified by PCR using primers (5'-GGAAGCTTTCCTGTCTGGACCATTCATTATGA-3' and 5'-GGCAGCTGCAGTGTAAGGGCCTCATAGTC-3') and rat ST cDNA as a template, digested with HindIII and PvuII, and ligated with NEP/ECD55–750. For TfR-NEP construction, human TfR cytoplasmic domain encoding residues 1–94 (TfR/CD1–94) was amplified by PCR using primers (5'-GGAAGCTTCTGTGTGGCAGTTCAGAATGATGG-3' and 5'-GGCCCGGGTTCTACCCCTTTACAATAGCC-3') and human liver cDNA library as a template, digested with HindIII and SmaI, and ligated with NEP/ECD55–750. For GAP43-NEP construction, human GAP43 N-terminal domain encoding residues 1–20 was fused to the N terminus of neprilysin by ligation of a EcoRV-digested fragment of neprilysin cDNA in pBluescript II and two pairs of oligonucleotides (5'-AGGGACGAGACAACCATGCTGTGCTGTATGAGAAGAACCAAACAGGTTGAAAAAAATGAT-3'/5'-TTCAACCTGTTTGGTTCTTCTCATACAGCACAGCATGGTTGTCTCGTCCCT-3' and 5'-GACGACCAAAAGATTATGGGCAAGTCAGAAAGTCAGATGGATATAACTGAT-3'/5'-ATCAGTTATATCCATCTGACTTTCTGACTTGCCCATAATCTTTTGGTCGTCATCATTTTT-3'). All cDNA constructs were verified by DNA sequencing and inserted into a pSFV1 vector (Invitrogen). To prepare a recombinant viral vector, each cRNA was transcribed from the SapI-linearized DNAs with SP6 RNA polymerase and then cotransfected together with pSFV-Helper1 RNA into baby hamster kidney cells using the Gene Pulser electroporation system (Bio-Rad) according to the manufacturer's instructions. The conditioned medium containing the recombinant viral vectors was collected at 24 h after transfection and stored at –80 °C until use. Primary cortical neurons were prepared from embryonic C57BL/6CrSlc mice as described previously (20). Infection was carried out by adding the viral vector solution to culture medium of cortical neurons (3–4 x 107 cells), which had been cultured for 7–9 days. At 16 h after the infection, the conditioned medium and the cell lysate were subjected to assay. When neurons were moved from in vivo conditions to in vitro conditions, the expression level of neprilysin declined for unknown reasons.

Western Blot Analysis and Assay for Neutral Endopeptidase Activity— Infected neurons were extensively washed with PBS, collected, and lysed with 1% Triton X-100 lysis buffer. Aliquots of the cell lysates were subjected to Western blot analysis using 56C6 and to assay for neutral endopeptidase activity using benzyloxycarbonyl-alanyl-alanyl-leucine-p-nitroanilide (Peptide Institute, Osaka, Japan) as a substrate, as described previously (26, 28). Neprilysin-dependent neutral endopeptidase activity was evaluated from the decrease in the rate of digestion caused by 10 µM thiorphan, a specific inhibitor of neprilysin. Protein concentrations were determined using a BCA protein assay kit (Pierce). For Western blot-based quantitative analysis, the intensities of immunoreactive bands were measured with a densitometer, LAS-3000 and Science Lab 2001 Image Gauge software (Fuji Photo Film, Tokyo, Japan).

Immunofluorescence Analysis—Primary neurons cultured on coverslips were infected with recombinant viral vectors and processed for double immunofluorescence staining after the cells had been treated with PBS containing 0.2% Triton X-100 as described previously (20), using the following sets of primary antibodies and appropriate fluorochrome-conjugated secondary antibodies as follows: 56C6/anti-rat MAP-2 antibody and Alexa 568-conjugated goat anti-mouse IgG/Alexa 488-conjugated goat anti-rabbit IgG, anti-BiP antibody/H-321, anti-adaptin {gamma} antibody/H-321 or anti-syntaxin 13 antibody/H-321, and Alexa 488-conjugated goat anti-mouse IgG/Alexa 568-conjugated goat anti-rabbit IgG. The immunofluorescence signals were observed under an IX70 inverted microscope incorporating a confocal laser scanning system FV300 (Olympus Optical, Tokyo, Japan). The digital images were captured with Fluoview, version 3.2 software (Olympus Optical), using a x100 objective. Eight-bit gray scale images were saved as digitized tagged image format files to retain maximum resolution. Colocalized areas of immunoreactive neprilysin and each marker protein in neurons were quantitated using image analysis software, MetaMorph, version 6.1 (Nippon Roper, Chiba, Japan). Each set of experiments was repeated at least two times.

Lipid Raft Fractionation—Virus-infected neurons (1 x 108 cells) were extensively washed with PBS, collected, and homogenized in MES-buffered saline (MBS: 25 mM MES, pH 6.5, 0.15 M NaCl) containing 1% Triton X-100, protease inhibitor mixture (CompleteTM, EDTA-free, Roche Diagnostics), and 0.7 µg/ml pepstatin A (Peptide Institute) through a 22-gauge needle (20 passages) on ice, followed by incubation at 4 °C for 30 min. After centrifugation at 2,000 x g for 10 min, 2 ml of the supernatant was mixed with an equivalent volume of 80% sucrose solution, and overlaid sequentially with 4 ml of 35% sucrose and 4 ml of 5% sucrose. The gradient was centrifuged at 39,000 rpm for 21 h with an SW41 rotor, and then 12 fractions (1 ml each) were collected from top to bottom. The pellet (fraction 13) was resuspended in 1 ml of MBS by sonication. Aliquots of all fractions were subjected to Western blot analysis to evaluate targeting of GAP43-NEP chimeric protein to the lipid raft fraction.

Measurement of A{beta} —Extracellular A{beta} in conditioned medium and intracellular A{beta} extracted with 6 M guanidine HCl from cultured neurons were measured by sandwich enzyme-linked immunosorbent assay (ELISA) as described previously (20, 29, 30), using BNT77/BA27 and BNT77/BC05 monoclonal antibodies for A{beta}40 and A{beta}42, respectively.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of Neprilysin Chimeric Proteins in Primary Cortical Neurons—Expression levels and relative molecular masses of wild-type, inactive mutant neprilysin, and the neprilysin chimeric proteins (Fig. 1) in primary neurons were analyzed by Western blotting at 16 h after the transfection with SFV vector (Fig. 2, A and B). Anti-neprilysin antibody 56C6 used here recognizes the extracellular domain of neprilysin, which is shared by all the constructs. Sec12-NEP showed a molecular mass of ~100 kDa, which is similar to that of the wild-type and mutant neprilysin. The molecular masses of ST-NEP, TfR-NEP, and GAP43-NEP were slightly altered from that of the wild type in accordance with the changes in the amino acid residues (see Fig. 1). The mutant, ST-NEP, TfR-NEP, and GAP43-NEP chimeric proteins were expressed at similar levels to the wild-type, but the expression level of Sec12-NEP was 60% lower than those of the others (Fig. 2B).



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 1.
Schematic diagram of wild-type neprilysin, inactive mutant neprilysin, and neprilysin chimeric proteins. Inactive mutant neprilysin has an amino acid (a.a.) substitution of Glu-585 to Val. Sec12-NEP, ST-NEP, TfR-NEP, and GAP43-NEP contain ER, TGN, early/recycling endosomes, and lipid raft fraction sorting signals as shown by black boxes, respectively. Numbers of amino acids in the white boxes represent those derived from neprilysin. TM, transmembrane.

 



View larger version (25K):
[in this window]
[in a new window]
  		FIG. 2.
Expression of neprilysin and neprilysin chimeric proteins in primary cortical neurons infected with SFV vector. A, cell lysates (5 µg) from cells expressing wild-type neprilysin (wt), inactive mutant neprilysin (mut), Sec12-NEP chimera (Sec12), ST-NEP chimera (ST), TfR-NEP chimera (TfR), and GAP43-NEP chimera (GAP43) were subjected to Western blot analysis with anti-neprilysin antibody 56C6. B, quantitative analysis of expression levels of neprilysin and neprilysin chimeric proteins. Intensities of immunoreactive bands shown in A were quantified as described under "Experimental Procedures." The linearity of the Western blot data has been confirmed. Each column with an error bar represents the mean ± S.D. of at least four independent experiments. C, neutral endopeptidase activity in cells expressing neprilysin and neprilysin chimeric proteins in the absence (open columns) and presence (closed columns) of thiorphan. Each column with an error bar represents the mean ± S.D. of at least three independent experiments.

 
We next determined the infectious efficiency of each viral vector to primary neurons using double immunofluorescence staining for neprilysin and a neuronal marker, MAP-2. The efficiencies, defined as the ratio of neprilysin-positive neurons to MAP-2-positive neurons, were 67.8 ± 12.3% for the wild-type, 69.1 ± 11.9% for the mutant, 74.6 ± 14.4% for Sec12-NEP, 54.8 ± 5.4% for ST-NEP, 64.7 ± 19.5% for TfR-NEP, and 62.0 ± 13.2% for GAP43-NEP infectants, indicating that all viral vectors had similar titers. Therefore, the reduced expression of Sec12-NEP was not caused by inefficient infection. We speculate that it probably was a consequence of rapid turnover of the expressed protein retained in ER rather than a reduction in transcription or translation, because Sec12-NEP and wild-type neprilysin share identical N-terminal amino acid sequences (see "Discussion" for further speculation).

Levels of thiorphan-sensitive endoproteolytic activity to hydrolyze benzyloxycarbonyl-alanyl-alanyl-leucine-p-nitroanilide were essentially consistent with the protein expression levels of the wild-type or neprilysin chimeric proteins except for Sec12-NEP (Fig. 2C). ST-NEP, TfR-NEP, and GAP43-NEP infectants showed peptidase activities comparable with that of the wild-type infectants. The mutant showed no enzymatic activity, as reported previously (20, 31). The activity in Sec12-NEP infectants was detectable and statistically significant (p < 0.05 as compared with the inactive mutant) but much lower than the others. However, this relatively low activity still seems to be sufficient to clear intracellular A{beta} (see below).

Localization of Neprilysin Chimeras in Neurons—We performed double immunofluorescence microscopy using organelle markers to confirm sorting of neprilysin chimeric proteins to an appropriate organelle (Fig. 3A). The wild-type neprilysin showed a partial co-localization with each organelle marker protein (Fig. 3A, panels 1, 3, and 5), indicating that wild-type neprilysin is not exclusively transported to or retained in a particular compartment. Expression of our targeting constructs successfully sorted Sec12-NEP, ST-NEP, and TfR-NEP to the expected organelle in neurons as follows. Sec12-NEP was extensively distributed in cell somas, showing localization similar to that of ER marker BiP (Fig. 3A, panel 2). ST-NEP was detected overlapping with a TGN marker adaptin {gamma} appearing as speckles near the nucleus (Fig. 3A, panel 4). TfR-NEP was detected as vesicular structures throughout the cytoplasm, colocalizing with an early/recycling endosomes marker syntaxin 13 (Fig. 3A, panel 6). The distributions of Sec12-NEP, ST-NEP, and TfR-NEP in the target organelles were increased 2.1-, 3.1-, and 2.1-fold, compared with those of wild-type neprilysin, respectively (p < 0.05). We next examined targeting of GAP43-NEP to the lipid raft fraction by using sucrose gradient fractionation after 1% Triton X-100 extraction at 4 °C (Fig. 3B). Flotilin-1, a marker protein of the lipid raft fraction, was detected as Triton X-100-insoluble proteins in fractions 4 and 5 (data not shown). GAP43-NEP as well as wild-type neprilysin were detected in the lipid raft fraction (Fig. 3B). The amount of GAP43-NEP in the raft fraction was 1.3-fold higher, compared with the case of wild-type neprilysin (p < 0.05). We did not employ the raft-targeting strategy described by Cailler et al. (32), in which a raft-targeting sequence was added at the C terminus of neprilysin, because such a modification may alter the conformation of the protein and thus may also modify the enzymatic properties of the peptidase.



View larger version (29K):
[in this window]
[in a new window]
  		FIG. 3.
Subcellular localization of neprilysin and neprilysin chimeric proteins in neurons. A, double immunofluorescence staining for neprilysin and organelle markers. Primary neurons transfected with wild-type neprilysin (panels 1, 3, and 5), Sec12-NEP (panel 2), ST-NEP (panel 4), and TfR-NEP (panel 6) were immunolabeled with antibodies to neprilysin (red) and organelle markers (green), BiP (panels 1 and 2), adaptin {gamma} (panels 3 and 4), or syntaxin 13 (panels 5 and 6), respectively. Bar, 20 µm. We have confirmed that all the fluorescence signals were within a linear dynamic range of 4096 levels. B, for lipid raft fractionation, primary neurons transfected with wild-type neprilysin or GAP43-NEP were homogenized and fractionated into 13 fractions. Fractions 4 and 5 are the lipid raft fraction as revealed by Western blot analysis using antibody to flotillin-1, a marker protein of lipid raft fraction (data not shown).

 
We also investigated whether the expressed proteins appeared on the cell surface or not by performing immunofluorescence in the absence of Triton X-100. Wild-type neprilysin, ST-NEP, TfR-NEP, and GAP43-NEP, but not Sec12-NEP, were observed on the cell surface (data not shown).

Effect of Targeting of Neprilysin to Particular Intracellular Compartments on Intracellular and Extracellular A{beta} Levels—We measured the amounts of A{beta} extracted with guanidine hydrochloride from the primary neurons expressing wild-type neprilysin, inactive mutant neprilysin, and neprilysin chimeric proteins (Fig. 4) in order to assess how much of the endogenously generated intracellular A{beta} was degraded. Both A{beta}40 and A{beta}42 were significantly decreased by the overexpression of wild-type neprilysin but not by that of inactive mutant neprilysin, as reported previously (20). All the chimeric proteins degraded A{beta}40 to an extent indistinguishable from that of wild-type neprilysin. A{beta}42 was much less degraded than A{beta}40 in all cases (0–10% versus 50–60%). Our speculation on the reason for the preferential clearance of intracellular A{beta}40 as compared with A{beta}42 is that A{beta}40 may be retained intracellularly for a longer time than A{beta}42, for instance through a recycling mechanism. This assumption is supported by the observation that ER-targeted neprilysin degrades A{beta}40 as sufficiently as wild type and other chimeras (see "Discussion" for further speculation). Most interesting, only wild-type neprilysin and ST-NEP degraded intracellular A{beta}42 to a significant degree. This is presumably because A{beta}42 is not generated in or recycled back to the ER (see "Discussion") and because endosomes are somewhat too acidic for neprilysin, the optimum pH for which is neutral, to more efficiently degrade A{beta} than in TGN.



View larger version (38K):
[in this window]
[in a new window]
  		FIG. 4.
Effects of neprilysin targeting to particular organelles or lipid raft fraction on the intracellular A{beta}40 and A{beta}42 levels. The A{beta}40 and A{beta}42 levels extracted with guanidine hydrochloride from infected neurons were measured by sandwich ELISA. The solid line shows the A{beta} levels of cells expressing inactive mutant neprilysin. Each column with an error bar represents the mean ± S.D. of at least three independent experiments. #, p < 0.01, significantly different from inactive mutant neprilysin by the Mann-Whitney U test.

 
We next examined the levels of A{beta}40 and A{beta}42 in the conditioned media of the infected cells (Fig. 5). Overexpression of the wild-type neprilysin, ST-NEP, TfR-NEP, and GAP43-NEP significantly decreased the amounts of extracellular A{beta}40 and A{beta}42 in a comparable manner (p < 0.01). ST-NEP and TfR-NEP differed from the wild-type neprilysin by clearing A{beta}40 in a slightly but significantly less efficient manner (p < 0.01). Again, A{beta}42 was cleared to a lesser extent than A{beta}40 (~60 versus 80%), but the difference was smaller than in the case of intracellular A{beta} clearance. In contrast, Sec12-NEP, targeted to ER, exhibited much weaker activity to reduce the extracellular A{beta} (~20%).



View larger version (37K):
[in this window]
[in a new window]
  		FIG. 5.
Effects of neprilysin targeting to particular organelles or lipid raft fractions on the extracellular A{beta}40 and A{beta}42 levels. The A{beta}40 and A{beta}42 levels in the conditioned medium of infected neurons were measured by sandwich ELISA. The solid line shows the A{beta} levels of cells expressing inactive mutant neprilysin. Each column with an error bar represents the mean ± S.D. of at least four independent experiments. *, p < 0.01, significantly different from wild-type neprilysin; #, p < 0.01, significantly different from inactive mutant neprilysin by the Mann-Whitney U test.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Despite a large number of cell biological studies of A{beta} metabolism and transport, it still remains unclear exactly where in neurons A{beta} is generated from amyloid precursor protein (APP). One of the aims of the present study was to obtain a clue to this question by targeting an A{beta}-degrading enzyme to particular cellular components.

The major technical limitation of our experimental paradigm employed here is that, although we can control the efficiency of infection by altering the amount of the viral vectors, the amount of protein expressed per cell cannot be controlled. This limitation makes it somewhat difficult to interpret the results in a quantitative manner. This assumption probably applies to the overexpression paradigm in most cell biological studies of APP and A{beta} metabolism thus far performed. However, because the A{beta} clearance in each case, intracellular or extracellular, remained unsaturated (Figs. 4 and 5), the following qualitative considerations should at least be valid.

We would like to comment on the difference in the ratio of A{beta}40 and A{beta}42 levels between the in vitro and in vivo situations. The ratio is ~7:1 in vitro and 3:1 in vivo (27). This difference is presumably due to the difference in the volume of the extracellular space and in the complexity of axo-dendritic structure and connections. Therefore, a simple enzymatic explanation for the observation indicating that A{beta}40 was more efficiently degraded than A{beta}42 in the present in vitro experimental paradigm (Figs. 4 and 5) is that the affinity of neprilysin for A{beta}42 is indistinguishable from that for A{beta}40 (26), and that the substrate present in a larger amount has a greater chance of encountering the enzyme. In contrast, A{beta}40 and A{beta}42 are degraded to an essentially identical extent in the brain in vivo as indicated by reverse genetic evidence (4). Most interesting, infusion of a cell-impermeable neprilysin inhibitor, thiorphan, into the brain elevated A{beta}42 but not A{beta}40 in the insoluble fraction (33). These previous observations, together with the finding that the relative efficiency of A{beta}42 degradation versus A{beta}40 degradation is greater extracellularly than intracellularly, imply that A{beta}40 and A{beta}42 are somewhat differentially metabolized in spatial terms. Degradation of A{beta}42 seems to be more closely associated with the outside surface of the cell than that of A{beta}40. The "outside surface" probably corresponds to the presynaptic membrane in vivo (27, 34).

Among the four chimeric proteins examined in the present study, only Sec12-NEP, targeted to ER, was significantly less abundantly detected than wild-type neprilysin in terms of both protein quantity and enzymatic activity. As discussed under "Results," this is likely to have been caused by metabolic instability of this chimera, which may be accounted for by premature glycosylation, because Sec12-NEP, but not the others, was sensitive to endoglycosidase H treatment (data not shown). Nevertheless, expression of Sec12-NEP reduced intracellular A{beta}40 in a manner comparable with that of wild-type neprilysin and the other chimeras. This indicates that the relatively small activity of neprilysin expressed in ER was sufficient to degrade intracellular A{beta}40, because wild-type neprilysin and all the other chimeras reside at least transiently in the ER after synthesis. Considering the previous reports describing A{beta} generation in ER, TGN, and endosome (14, 15, 35), our observation implies that a certain pool of intracellular A{beta}40 is retained in or recycled back to the ER in cultured neurons, as it is unlikely that the ER is a major site of A{beta} generation from APP (36). If aging causes such a pool of intracellular A{beta} to remain abnormally unmetabolized, pathological intraneuronal A{beta} accumulation (37–39) may arise, possibly leading to ER stresses. Part of this ER-resident A{beta} may be transported to the cytoplasm and undergo degradation catalyzed by proteosome or insulin-degrading enzyme (40). Of particular interest is the fact that intracellular A{beta}42 was cleared significantly only by wild-type neprilysin and TGN-targeted ST-NEP (Fig. 4). This observation is consistent with our speculation that metabolism of A{beta}42 takes place somewhat later than that of A{beta}40 in the intracellular trafficking processes.

In clear contrast to intracellular A{beta}, extracellular A{beta} was poorly degraded by Sec12-NEP, which did not appear on the cell surface. Because the wild-type neprilysin and all the other chimeras were detected on the outside of neurons, the results indicate that the majority of extracellular A{beta} degradation takes place on the cell surface in the present experimental paradigm. It was rather unexpected that GAP43-NEP, targeted to lipid rafts, failed to degrade A{beta} more efficiently than wild-type neprilysin, because a number of studies have indicated that A{beta} generation takes place in this microdomain (18, 19). The results can be accounted for by assuming that the extracellular A{beta} was proteolyzed by neprilysin after being secreted into the conditioned medium in the present in vitro paradigm. We would like to draw attention to the fact that that although the ratio of soluble A{beta} to insoluble A{beta} is ~400:1 in vitro, the ratio in vivo is 3:1 (27). Therefore, there still remains a possibility that targeting neprilysin to lipid rafts may improve the efficiency of A{beta} degradation under in vivo conditions, in which both neprilysin and A{beta} are axonally transported to presynapses (27, 34, 41–44), and A{beta} is likely to associate with such raft components as ganglioside and cholesterol (45, 46) and such raft-interacting proteins as apolipoproteins J and E (47–50). One way to further examine this possibility would be to utilize the in vivo gene transfer approach (27).


   FOOTNOTES
 
* This work was supported by research grants from RIKEN Brain Science Institute and the Ministry of Education, Culture, Sports, Science and Technology of Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed. Tel.: 81-48-467-9715; Fax: 81-48-467-9716; E-mail: saido{at}brain.riken.go.jp.

1 The abbreviations used are: A{beta}, amyloid {beta} peptide; AD, Alzheimer's disease; ER, endoplasmic reticulum; TGN, trans-Golgi network; ST, {beta}-galactoside {alpha}2,6-sialyltransferase; TfR, transferrin receptor; GAP43, growth-associated protein 43; SFV, Semliki Forest virus; BiP, immunoglobulin heavy chain-binding protein; MAP-2, microtubule-associated protein-2; NEP, neprilysin; ELISA, enzyme-linked immunosorbent assay; APP, amyloid precursor protein; MES, 2-(N-morpholino)ethanesulfonic acid. Back

2 N. Iwata and T. C. Saido, unpublished data. Back


   ACKNOWLEDGMENTS
 
We thank E. Hosoki for technical assistance. We also thank Dr. Y. Ihara for kindly providing the rabbit anti-rat MAP-2 antiserum, Dr. Y. Hashimoto for rat ST cDNA, Dr. B. De Strooper for the viral vector, Takeda Chemical Industries, Ltd. for the monoclonal antibodies to A{beta} for ELISA, and Dr. A. Nakano for advice about organelle targeting.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Selkoe, D. J. (2001) Physiol. Rev. 81, 741–766[Abstract/Free Full Text]
  2. Saido, T. C. (2000) Neurosci. News 3, 52–62
  3. Hardy, J. (1997) Trends Neurosci. 20, 154–159[CrossRef][Medline] [Order article via Infotrieve]
  4. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H. J., and Saido, T. C. (2001) Science 292, 1550–1552[Abstract/Free Full Text]
  5. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., and Guenette, S. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 4162–4167[Abstract/Free Full Text]
  6. Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B., and Thiele, D. L. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 6221–6226[Abstract/Free Full Text]
  7. Eckman, E. A., Watson, M., Marlow, L., Sambamurti, K., and Eckman, C. B. (2003) J. Biol. Chem. 278, 2081–2084[Abstract/Free Full Text]
  8. Saito, T., Takaki, Y., Iwata, N., Trojanowski, J., and Saido, T. C. (2003) Sci. Aging Knowledge Environ. 2003 3:PE1
  9. Saido, T. C., and Nakahara, H. (2003) in A{beta} Metabolism and Alzheimer's Disease (Saido, T. C., ed) pp. 61–80, Landes Bioscience, Georgetown, TX
  10. Saria, A., Hauser, K. F., Traurig, H. H., Turbek, C. S., Hersh, L., and Gerard, C. (1997) Neurosci. Lett. 234, 27–30[CrossRef][Medline] [Order article via Infotrieve]
  11. Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S., and Saido, T. C. (2002) J. Neurosci. Res. 70, 493–500[CrossRef][Medline] [Order article via Infotrieve]
  12. Yasojima, K., Akiyama, H., McGeer, E. G., and McGeer, P. L. (2001) Neurosci. Lett. 297, 97–100[CrossRef][Medline] [Order article via Infotrieve]
  13. Yasojima, K., McGeer, E. G., and McGeer, P. L. (2001) Brain Res. 919, 115–121[CrossRef][Medline] [Order article via Infotrieve]
  14. Echeverria, V., and Cuello, A. C. (2002) Mol. Neurobiol. 26, 299–316[CrossRef][Medline] [Order article via Infotrieve]
  15. Ling, Y., Morgan, K., and Kalsheker, N. (2003) Int. J. Biochem. Cell Biol. 35, 1505–1535[CrossRef][Medline] [Order article via Infotrieve]
  16. Angelisova, P., Drbal, K., Horejsi, V., and Cerny, J. (1999) Blood 93, 1437–1439[Free Full Text]
  17. Kanemitsu, H., Tomiyama, T., and Mori, H. (2003) Neurosci. Lett. 23, 113–116
  18. Wolozin, B. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 5371–5373[Free Full Text]
  19. Cordy, J. M., Hussain, I., Dingwall, C., Hooper, N. M., and Turner, A. J. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 11735–11740[Abstract/Free Full Text]
  20. Hama, E., Shirotani, K., Masumoto, H., Sekine-Aizawa, Y., Aizawa, H., and Saido, T. C. (2001) J. Biochem. (Tokyo) 130, 721–726[Abstract/Free Full Text]
  21. Sato, M., Sato, K., and Nakano, A. (1996) J. Cell Biol. 134, 279–293[Abstract/Free Full Text]
  22. Colley, K. J., Lee, E. U., and Paulson, J. C. (1992) J. Biol. Chem. 267, 7784–7793[Abstract/Free Full Text]
  23. West, A. E., Neve, R. L., and Buckley, K. M. (1997) J. Neurosci. 17, 6038–6047[Abstract/Free Full Text]
  24. Arni, S., Keilbaugh, S. A., Ostermeyer, A. G., and Brown, D. A. (1998) J. Biol. Chem. 273, 28478–28485[Abstract/Free Full Text]
  25. Nukina, N., and Ihara, Y. (1983) Proc. Jpn. Acad. 59, 284–287
  26. Shirotani, K., Tsubuki, S., Iwata, N., Takaki, Y., Harigaya, W., Maruyama, K., Kiryu-Seo, S., Kiyama, H., Iwata, H., Tomita, T., Iwatsubo, T., and Saido, T. C. (2001) J. Biol. Chem. 276, 21895–21901[Abstract/Free Full Text]
  27. Iwata, N., Mizukami, H., Shirotani, K., Takaki, Y., Muramatsu, S., Lu, B., Gerard, N. P., Gerard, C., Ozawa, K., and Saido, T. C. (2004) J. Neurosci. 24, 991–998[Abstract/Free Full Text]
  28. Takaki, Y., Iwata, N., Tsubuki, S., Taniguchi, S., Toyoshima, S., Lu, B., Gerard, N. P., Gerard, C., Lee, H. J., Shirotani, K., and Saido, T. C. (2000) J. Biochem. (Tokyo) 128, 897–902[Abstract/Free Full Text]
  29. Suzuki, N., Cheung, T. T., Cai, X. D., Odaka, A., Otvos, L., Jr., Eckman, C., Golde, T. E., and Younkin, S. G. (1994) Science 264, 1336–1340[Abstract/Free Full Text]
  30. Asami-Odaka, A., Ishibashi, Y., Kikuchi, T., Kitada, C., and Suzuki, N. (1995) Biochemistry 34, 10272–10278[CrossRef][Medline] [Order article via Infotrieve]
  31. Devault, A., Nault, C., Zollinger, M., Fournie-Zaluski, M. C., Roques, B. P., Crine, P., and Boileau, G. (1988) J. Biol. Chem. 263, 4033–4040[Abstract/Free Full Text]
  32. Cailler, F., Howell, S., and Crine, P. (1998) Biochim. Biophys. Acta 1415, 1–9[Medline] [Order article via Infotrieve]
  33. Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H. J., Hama, E., Sekine-Aizawa, Y., and Saido, T. C. (2000) Nat. Med. 6, 143–150[CrossRef][Medline] [Order article via Infotrieve]
  34. Fukami, S., Watanabe, K., Iwata, N., Haraoka, J., Lu, B., Gerard, N. P., Gerard, C., Fraser, P., Westaway, D., St. George-Hyslop, P., and Saido, T. C. (2002) Neurosci. Res. 43, 39–56[CrossRef][Medline] [Order article via Infotrieve]
  35. Almeida, C. G., Takahashi, R. H., Kearney, P. F., Yu, F., Li, F., Lin, M. T., Greengard, P., Snyder, E., and Gouras, G. K. (2003) Program No. 667.8, Society for Neuroscience, Washington, D. C.
  36. Iwata, H., Tomita, T., Maruyama, K., and Iwatsubo, T. (2001) J. Biol. Chem. 276, 21678–21685[Abstract/Free Full Text]
  37. Chui, D. H., Tanahashi, H., Ozawa, K., Ikeda, S., Checler, F., Ueda, O., Suzuki, H., Araki, W., Inoue, H., Shirotani, K., Takahashi, K., Gallyas, F., and Tabira, T. (1999) Nat. Med. 5, 560–564[CrossRef][Medline] [Order article via Infotrieve]
  38. Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., Beyreuther, K., and Bayer, T. A. (2001) Neurosci. Lett. 306, 116–120[CrossRef][Medline] [Order article via Infotrieve]
  39. Shie, F. S., LeBoeur, R. C., and Jin, L. W. (2003) Neuroreport 14, 123–129[CrossRef][Medline] [Order article via Infotrieve]
  40. Schmitz, A., Schneider, A., Kummer, M. P., and Herzogm, V. (2004) Traffic 5, 89–101[CrossRef][Medline] [Order article via Infotrieve]
  41. Marcel, D., Pollard, H., Verroust, P., Schwartz, J. C., and Beaudet, A. (1990) J. Neurosci. 10, 2804–2817[Abstract]
  42. Barnes, K., Turner, A. J., and Kenny, A. J. (1993) Neuroscience 53, 1073–1082[CrossRef][Medline] [Order article via Infotrieve]
  43. Koo, E. H., Sisodia, S. S., Archer, D. R., Martin, L. J., Weidemann, A., Beyreuther, K., Fischer, P., Masters, C. L., and Price, D. L. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1561–1565[Abstract/Free Full Text]
  44. Buxbaum, J. D., Thinakaran, G., Koliatsos, V., O'Callahan, J., Slunt, H. H., Price, D. L., and Sisodia, S. S. (1998) J. Neurosci. 18, 9629–9637[Abstract/Free Full Text]
  45. Yanagisawa, K., Odaka, A., Suzuki, N., and Ihara, Y. (1995) Nat. Med. 1, 1062–1066[CrossRef][Medline] [Order article via Infotrieve]
  46. Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., and Matsuzaki, K. (2002) Biochemistry 41, 7385–7390[CrossRef][Medline] [Order article via Infotrieve]
  47. Matsubara, E., Frangione, B., and Ghiso, J. (1995) J. Biol. Chem. 270, 7563–7567[Abstract/Free Full Text]
  48. DeMattos, R. B., O'dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A., Bales, K. R., Paul, S. M., Aronow, B. J., and Holtzman, D. M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10843–10848[Abstract/Free Full Text]
  49. Holtzman, D. M., Fagan, A. M., Mackey, B., Tenkova, T., Sartorius, L., Paul, S. M., Bales, K., Ashe, K. H., Irizarry, M. C., and Hyman, B. T. (2000) Ann. Neurol. 47, 739–747[CrossRef][Medline] [Order article via Infotrieve]
  50. Fagan, A. M., Watson, M., Parsadanian, M., Bales, K. R., Paul, S. M., and Holtzman, D. M. (2002) Neurobiol. Dis. 9, 305–318[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
W. J. Meilandt, M. Cisse, K. Ho, T. Wu, L. A. Esposito, K. Scearce-Levie, I. H. Cheng, G.-Q. Yu, and L. Mucke
Neprilysin Overexpression Inhibits Plaque Formation But Fails to Reduce Pathogenic A{beta} Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice
J. Neurosci., February 18, 2009; 29(7): 1977 - 1986.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Iijima-Ando, S. A. Hearn, L. Granger, C. Shenton, A. Gatt, H.-C. Chiang, I. Hakker, Y. Zhong, and K. Iijima
Overexpression of Neprilysin Reduces Alzheimer Amyloid-{beta}42 (A{beta}42)-induced Neuron Loss and Intraneuronal A{beta}42 Deposits but Causes a Reduction in cAMP-responsive Element-binding Protein-mediated Transcription, Age-dependent Axon Pathology, and Premature Death in Drosophila
J. Biol. Chem., July 4, 2008; 283(27): 19066 - 19076.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/29/30259    most recent
M401891200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hama, E.
Right arrow Articles by Saido, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hama, E.
Right arrow Articles by Saido, T. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement